Concepts (102)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcopenia | 2 | 2023 | 378 | 0.740 |
Why?
|
| Neuroma, Acoustic | 1 | 2022 | 456 | 0.600 |
Why?
|
| Cerebellar Neoplasms | 1 | 2022 | 571 | 0.580 |
Why?
|
| Medulloblastoma | 1 | 2022 | 658 | 0.570 |
Why?
|
| Brain Neoplasms | 7 | 2022 | 9071 | 0.470 |
Why?
|
| Hearing Loss | 1 | 2022 | 784 | 0.470 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1050 | 0.460 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 1182 | 0.430 |
Why?
|
| Radiosurgery | 1 | 2022 | 1328 | 0.400 |
Why?
|
| Cranial Irradiation | 3 | 2019 | 385 | 0.350 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 21056 | 0.270 |
Why?
|
| Temporal Muscle | 1 | 2023 | 36 | 0.220 |
Why?
|
| Growth Charts | 1 | 2023 | 60 | 0.210 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 3 | 2021 | 1643 | 0.190 |
Why?
|
| Protons | 2 | 2022 | 1073 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2023 | 3537 | 0.150 |
Why?
|
| Bibliometrics | 1 | 2022 | 357 | 0.150 |
Why?
|
| Truth Disclosure | 1 | 2022 | 433 | 0.150 |
Why?
|
| Hearing | 1 | 2022 | 505 | 0.150 |
Why?
|
| Retrospective Studies | 12 | 2023 | 81514 | 0.140 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 11206 | 0.140 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 6832 | 0.130 |
Why?
|
| Taxoids | 2 | 2017 | 665 | 0.130 |
Why?
|
| Parotid Gland | 1 | 2017 | 177 | 0.130 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2023 | 961 | 0.130 |
Why?
|
| Androgen Antagonists | 1 | 2024 | 1411 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 2895 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2023 | 1534 | 0.120 |
Why?
|
| Organs at Risk | 1 | 2017 | 352 | 0.120 |
Why?
|
| Doxorubicin | 2 | 2017 | 2230 | 0.100 |
Why?
|
| Dacarbazine | 1 | 2015 | 552 | 0.100 |
Why?
|
| Prognosis | 6 | 2019 | 29922 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2022 | 5389 | 0.100 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2015 | 614 | 0.100 |
Why?
|
| Radiotherapy Dosage | 4 | 2021 | 2865 | 0.090 |
Why?
|
| Temporal Lobe | 1 | 2019 | 1714 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2022 | 8529 | 0.090 |
Why?
|
| Humans | 24 | 2024 | 765968 | 0.090 |
Why?
|
| Prostatic Neoplasms | 2 | 2024 | 11083 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6499 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 2921 | 0.080 |
Why?
|
| Communication | 1 | 2022 | 3916 | 0.070 |
Why?
|
| Neoplasms | 3 | 2022 | 22340 | 0.070 |
Why?
|
| Research Design | 1 | 2022 | 6209 | 0.070 |
Why?
|
| Health Personnel | 1 | 2020 | 3390 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 8041 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 13451 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 5370 | 0.060 |
Why?
|
| Adult | 7 | 2022 | 223044 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2022 | 39193 | 0.060 |
Why?
|
| Quality of Life | 2 | 2024 | 13462 | 0.060 |
Why?
|
| Quality of Health Care | 1 | 2020 | 4300 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9373 | 0.060 |
Why?
|
| Middle Aged | 10 | 2023 | 223009 | 0.060 |
Why?
|
| Glioblastoma | 2 | 2015 | 3459 | 0.060 |
Why?
|
| Pandemics | 2 | 2022 | 8703 | 0.050 |
Why?
|
| Aged | 7 | 2023 | 171117 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 12509 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3100 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3223 | 0.050 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2023 | 337 | 0.050 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 26318 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 11868 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2022 | 24282 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2019 | 10070 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 59489 | 0.040 |
Why?
|
| Time Factors | 2 | 2019 | 40065 | 0.040 |
Why?
|
| Female | 10 | 2023 | 396112 | 0.040 |
Why?
|
| Photons | 1 | 2021 | 572 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2022 | 65188 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2022 | 54802 | 0.040 |
Why?
|
| Rectum | 1 | 2021 | 896 | 0.030 |
Why?
|
| Male | 10 | 2024 | 363698 | 0.030 |
Why?
|
| Young Adult | 1 | 2022 | 59889 | 0.030 |
Why?
|
| Obesity | 1 | 2017 | 13076 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2024 | 1950 | 0.030 |
Why?
|
| Adolescent | 1 | 2022 | 88835 | 0.030 |
Why?
|
| Radiation Protection | 1 | 2017 | 424 | 0.030 |
Why?
|
| Prostate | 1 | 2021 | 1755 | 0.030 |
Why?
|
| New York | 1 | 2015 | 880 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 13648 | 0.030 |
Why?
|
| Brain | 1 | 2019 | 27171 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2015 | 2263 | 0.020 |
Why?
|
| Age Distribution | 1 | 2015 | 2858 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2020 | 2778 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2023 | 41649 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2016 | 2887 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 2659 | 0.020 |
Why?
|
| Mastectomy | 1 | 2016 | 1847 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 3413 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 10383 | 0.020 |
Why?
|
| United States | 2 | 2022 | 72903 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 14652 | 0.010 |
Why?
|
| Algorithms | 1 | 2022 | 14071 | 0.010 |
Why?
|
| Disease Progression | 1 | 2019 | 13632 | 0.010 |
Why?
|
| Survival Rate | 1 | 2015 | 12795 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2019 | 22223 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2017 | 13039 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 20124 | 0.010 |
Why?
|
| Prevalence | 1 | 2015 | 15842 | 0.010 |
Why?
|
| Child | 1 | 2023 | 80564 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 74840 | 0.000 |
Why?
|
Concepts
(102)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(70)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_